Felix Kesselring

Dr Felix Kesselring, LL.M. (LSE)

Counsel

CMS von Erlach Poncet Ltd.
Dreikönigstrasse 7
P.O. Box
8022 Zurich
Switzerland
Languages German, English, French

Felix Kesselring’s practice focuses on public and administrative law, public procedural law and compliance.

He specialises in advising Swiss and international companies in regulated markets such as healthcare, pharma, medical devices, biotechnology, foodstuffs and cosmetics. He regularly represents his clients before administrative authorities, administrative criminal authorities and courts and advises on corporate and M&A transactions.

Felix Kesselring received his law degree from the University of Zurich and the University of Strasbourg. He holds a postgraduate degree (LL.M. in Public Law) from the London School of Economics and Political Science (LSE) and received his PhD (Dr. iur.) from the University of Basel. Felix Kesselring has been working as an attorney-at-law since 2009. In addition, he worked as a seconded legal counsel for a Swiss-based multinational pharmaceutical company.

Felix Kesselring is a lecturer at the Swiss Federal Institute of Technology (ETH) and regularly publishes in his areas of expertise.

more less

Relevant experience

  • Advising various pharmaceutical companies on negotiating and drafting pharmatypical contracts (research contracts, development contracts, contracts for clinical studies, contract manufacturing agreements, licensing agreements, distribution agreements, etc.)
  • Providing regulatory advice and procedural representation to various pharmaceutical companies in relation to operating authorisations (manufacturing, wholesale, import, export, trading abroad) and special authorisations
  • Advising various pharmaceutical companies in selling their products to wholesalers and medical service providers, particularly in the area of advertising and monetary benefits (discounts, kickbacks, further and continued education contributions, sponsoring, etc.)
  • Advising and representing various pharmaceutical companies in appeal proceedings before the Federal Administrative Court and the Federal Supreme Court in relation to the inclusion of their medicinal products in the list of reimbursable products (Specialities List) and the periodic review of the listing conditions
  • Advising a world-leading medical device manufacturer on all regulatory product issues
  • Advising a retailer in relation to the purchase of medical devices and the implementation of its medical devices compliance programme
  • Advising a retailer and a major medical device manufacturer on political initiatives to amend laws and regulations
  • Advising and representing a medical service provider in administrative and administrative criminal proceedings in relation to transplants and transplant products
  • Advising various service providers in relation to stem cell therapies and therapies involving cell extracts
  • Advising and supporting various food companies on retaking and recalling of foodstuffs
  • Advising and representing food and cosmetics manufacturers in relation to administrative procedures for alleged violation of customs regulations
  • Advising and representing a world-leading cosmetics company in its appeal to the Federal Administrative Court against a Swiss marketing ban of certain foreign cosmetics
  • Advising and representing hospitals and clinics in relation to the allocation to cantonal hospital lists and to the inter-cantonal hospital list of highly-specialised medicine (HSM)
  • Advising and representing hospitals and clinics in sovereign tariff setting procedures and the associated appeal procedures, particularly in the areas of SwissDRG and TARMED
  • Advising several Swiss physicians in the area of professional law, particularly advertising, monetary benefits and authorisations
  • Advising and representing foreign physicians in relation to the recognition of foreign further education for a Swiss specialist title
  • Providing comprehensive regulatory advice to the European market leader in the area of laboratory diagnostics, particularly with regard to tariff and other social security related issues
more less

Education

  • 2017 – PhD in Law, University of Basel, Switzerland
  • 2012 – LL.M. in Public Law, London School of Economics and Political Science, London, United Kingdom
  • 2009 – Attorney-at-law, admitted to all Swiss courts
  • 2006 – lic. iur., University of Zurich, Switzerland
  • 2004/2005 – University Robert Schuman, Strasbourg, France 
more less

Memberships

  • Swiss Association of Jurists (SJV)
  • Zurich Bar Association (ZAV)
  • Swiss Bar Association (SAV)
  • British-Swiss Chamber of Commerce (BSCC)
more less

Publications

  • Kesselring Felix, Advertising, integrity and transparency (chapters), in: Schroeder de Castro Lopes Barbara/Schallnau Judith, Life Sciences Law, Zurich/St. Gallen 2019, 127–131 and 134–135
  • Kesselring Felix, Revidiertes Fortpflanzungsmedizingesetz, Die neuen Bestimmungen zur Zulässigkeit der Präimplantationsdiagnostik im Überblick, in: Life Science Recht 4/2018, 255–260
  • Kesselring Felix, Neue Regeln für Rabatte, Kickbacks und Sponsoring, Die revidierten Bestimmungen im Heilmittel- und Krankenversicherungsrecht im Überblick, in: Life Science Recht 3/2018, 159–173
  • Kesselring Felix, Vorteile und Vergünstigungen im Heilmittel- und Versicherungsrecht, Kommentar zu Art. 55 und 56 HMG (heilmittelrechtliche Integrität und Transparenz) und Art. 56 Abs. 3 lit. b und Abs. 3bis KVG (krankenversicherungsrechtliche Weitergabepflicht), PhD thesis Basel, Zurich/St. Gallen 2018
  • Kesselring Felix, Umstrittene Planungsentscheide im Bereich der hochspezialisierten Medizin (HSM), in: CMS Law-Now of 13 December 2017
  • Kesselring Felix/Brauchbar Birkhäuser Simone, More Cocoa Powder for the Swiss? The Swiss view on the "Nutella gap", in: CMS Law-Now of 4 December 2017
  • Kesselring Felix, Ausführungsrecht zur ordentlichen Revision des Heilmittelrechts, in: Life Science Recht 1/2018, 39–42
  • Kesselring Felix, Erste Preissenkungsverfügungen nach der Wiederaufnahme der periodischen Arzneimittelpreisüberprüfungen, in: CMS Law-Now of 13 October 2017
  • Kesselring Felix, Neue Regelungen zur Integrität und Transparenz im Heilmittelhandel, in: LES (Licensing Executives Society) Newsletter September 2017, 2–3
  • Kesselring Felix/Kohler Stefan, Is clampdown on Swiss stem cell therapies justified? in: China Business Law Journal Volume 7 Issue 4 April 2016, 78–79
  • Kesselring Felix/Hettich Peter, Erwerb und Bau von Immobilien in der Schweiz, in: VISCHER AG (ed.), Erfolgsfaktoren für Investitionen in der Schweiz, Zurich 2016, 19–24
  • Kesselring Felix, Arzneimittelhaftung und Arzthaftung, in: Psychiatrie und Neurologie 5/2015, 20–21
  • Kesselring Felix, Aktuelles aus der Preissenkungspraxis des BAG, Newsletter VISCHER AG of September 2013
  • Kesselring Felix/Waldner Michael, Festsetzungsverfahren könnten unter Kostendruck häufiger werden, in: Competence 1-2/2013, 24–25
  • Kesselring Felix/Hettich Peter, Erwerb und Bau von Immobilien in der Schweiz, in: VISCHER AG (ed.), Erfolgsfaktoren für Investitionen in der Schweiz, Zurich 2012, 21–26
  • Kesselring Felix, First Fundamental Decision of the Federal Supreme Court of Switzerland on Cost Effectiveness in the Area of Human Healthcare, in: European Journal of Risk Regulation (EJRR) 3/2011, 442–446
  • Kesselring Felix, Kosten-/Nutzen-Beziehung im Bereich der menschlichen Gesundheit, in: AJP/PJA 4/2011, 573–577
more less

Lectures list

  • Verwaltungsstrafrechtliche Probleme der Transparenzpflicht im künftigen Art. 56 HMG, University of Zurich, Zurich, 7 November 2018
  • The Lawyers' Perspective on Reproduction Medicine, University of Innsbruck, Summer ELSA Law School on Medical and Health Law, 6 July 2018, Innsbruck
  • Revision HMG und KVG: Rabatte, Kickbacks, Sponsoring, CMS Frühstücks-Veranstaltung, 19 April 2018, Zurich
  • Product Piracy – View from Switzerland (Medicrime Convention), CMS Webinar, 6 February 2018, Zurich
  • Risks and Investigations in the Lifesciences Sector, CMS Global Lifesciences Forum 2017, 7 November 2017, London
  • Wird alles anders? Aktuelles zum baldigen Inkrafttreten der neuen Regeln über die geldwerten Vorteile (Art. 55 f. nHMG und Art. 56 nKVG), Seminar "Aktuelle Entwicklungen im Bereich Life Sciences" des Europa Institut an der Universität Zürich, 3 October 2017, Zurich
  • Kostenübernahme von Medikamenten im Rahmen der Invaliden- und Krankenpflegeversicherung, Duchenne Konferenz Schweiz 2016, 2 September 2016, Lucerne
  • Ändert sich etwas durch den "Imatinib"-Patentablauf in der Schweiz?, 13. Treffen der GIST-Gruppe Schweiz, 22 April 2016, Zurich
  • Medizinprodukteregulierung in der Schweiz, forum digitale gesundheit, Medizinprodukte im Zeitalter der Digitalisierung, 2 February 2016, Zurich
  • Rechtsentwicklungen im ambulanten Bereich (insbesondere die KVG-Revision betreffend Steuerung des ambulanten Bereichs), Business Talk of 7 May 2015, Zurich
  • Regulation of drugs, medical devices, medical software, web care etc., and the proposed revision of the EU Medical Devices Directives, AIJA-Tagung Life Sciences 2.0, 13 March 2015, Basel
  • Vergütung von Off-Label-Therapien – Nutzenbewertungsmodelle auf dem rechtlichen Prüfstand, Business Talk of 10 November 2014, Zurich
  • Geldwerte Vorteile nach dem revidierten Heilmittelgesetz – Risiken und Nebenwirkungen, Business Talk of 25 September 2014, Basel
  • Einkauf von Medikamenten nach revidiertem Heilmittelgesetz, Business Talk of 11 September 2014, Zurich
  • IV/UV/MV-Tarife, Business Talk of 6 May 2013, Zurich
more less

Feed

Show only
27/02/2019
CMS ad­vised Syn­cona Ltd on in­vest­ment in Ana­ve­on AG
13/12/2017
Um­strittene Planung­sentscheide im Bereich der hoch­spezi­al­is­ier­ten...
Die Planung der hoch­spezi­al­is­ier­ten Med­iz­in (HSM) wird von al­len Kantonen ge­mein­sam durchge­führt. Die Entscheide des zuständi­gen Beschlus­sor­gans sind oft um­strit­ten. Nicht alle sind aber gleich­er­massen an­fecht­bar.
17/12/2018
Pub­lic pro­cure­ment guide
04/12/2017
More Co­coa Powder for the Swiss? The Swiss view on the "Nu­tella gap"
Should Fer­rero, the pro­du­cer of Nu­tella, be hindered to pro­duce a Swiss-style Nu­tella just for the Swiss mar­ket with more co­coa powder than the "nor­mal" Nu­tella? On the as­sump­tion that Swiss con­sumers have a spe­cial taste, can Nestlé ad­just its Ness­presso cap­sules.
17/04/2018
Life Sci­ences & Health­care Prac­tice Group Switzer­land
16/01/2018
New part­ner and new coun­sels at CMS